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Abstract
Drug substances are at risk of contamination with N-nitrosamines (NAs), well-known carcinogenic agents, during
synthesis processes and/or long-term storage. Therefore, in this study, we developed an efﬁcient data-based screening
approach to systemically assess marketed products and investigated its scalability for beneﬁting both regulatory
agencies and pharmaceutical industries. A substructure-based screening method employing DataWarrior, an opensource software, was established to evaluate the risks of NA impurities in drug substances. Eight NA substructures
containing susceptible amino sources for N-nitrosation have been identiﬁed as screening targets: dimethylamine (DMA),
diethylamine, isopropylethylamine, diisopropylamine, N-methyl-2-pyrrolidone, dibutylamine, methylphenylamine, and
tetrazoles. Our method detected 192 drug substances with a theoretical possibility of NA impurity, 141 of which had not
been reported previously. In addition, the DMA moiety was signiﬁcantly dominant among the eight NA substructures.
The results were validated using data from the literature, and a high detection sensitivity of 0.944 was demonstrated.
Furthermore, our approach has the advantage of scalability, owing to which 31 additional drugs with suspected NAcontaminated substructures were identiﬁed using the substructures of 1-methyl-4-piperazine in rifampin and 1-cyclopentyl-4-piperazine in rifapentine. In conclusion, the reported substructure-based approach provides an effective and
scalable method for the screening and investigation of NA impurities in various pharmaceuticals and might be used as
an ancillary technique in the ﬁeld of pharmaceutical quality control for risk assessments of potential NA impurities.
Keywords: Cheminformatics, Data mining, Nitrosamines, Risk assessment, Total quality management

1. Introduction

N

-nitrosamines (NAs) are potent genotoxic
agents that can affect several animal species
and are classiﬁed as potentially carcinogenic to
humans by the International Agency for Research
on Cancer (IARC) [1]. They are referred to as “cohort

of concern” compounds in the International Conference on Harmonisation (ICH) guidance for industry M7 (R1) Assessment and Control of DNA
Reactive (Mutagenic) Impurities in Pharmaceuticals to
Limit Potential Carcinogenic Risk [2].
In recent years, the presence of unexpected NA impurities in various pharmaceuticals has been reported.
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In May 2018, valsartan was reported as the ﬁrst drug to
be contaminated with the NA impurities N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), and this event triggered a series of
drug recall actions worldwide [3]. Valsartan, like the
other angiotensin II receptor blockers (ARBs), has a
tetrazole ring. The speciﬁc set of reactants and reaction
conditions used in the chemical synthesis of this ring
has been linked to the formation of NA impurities [4].
Hence, the structural characteristics of tetrazole rings
in pharmaceuticals may be utilized to reveal the
possible existence of NA impurities owing to the ﬁrm
relationship between the reactants and the synthesized product. In addition to ARBs, other drugs have
been reported to be contaminated with NAs resulting
from different routes of chemical synthesis. In
September 2019, the FDA announced that NDMA was
found in ranitidine, a common antihistamine antacid,
and its structural sibling, nizatidine [5,6]. Taken
together, these ﬁndings provide a rationale to search
for a method to assess the risk of NA contamination
based on the substructures of pharmaceuticals.
In April 2020, the FDA requested all ranitidine
products to be immediately removed from the market.
This recall was made following the discovery that ranitidine products ramped up NDMA impurities during storage, especially at higher temperatures [7,8].
Other antacids (e.g., famotidine and lansoprazole)
seemed unaffected by the storage conditions. In May
2020, extended-release metformin products were
found to be contaminated by NDMA at levels above the
acceptable limit, and a voluntary recall was posted on
these products in the United States [6]. Both metformin
and ranitidine contain a dimethylamine moiety in their
structures, suggesting that a speciﬁc amine-containing
substructure can be utilized to pinpoint the possible
existence of NA impurities in pharmaceuticals.
As recommended in the ICH Guideline M7 [2],
potentially carcinogenic compounds should be
controlled if “the existence of such substances is
reasonably expected in the ﬁnal drug substance or
product.” From the pharmacovigilance point of view,
the development of an effective method to detect NA
impurities in pharmaceuticals for risk assessment and
control is indeed required in the post-marketing
surveillance of the drug products. Recent information
gathered by the FDA regarding the root causes of NA
impurities present in drug products suggests that the
structural characteristics of pharmaceutical components, including active pharmaceutical ingredients
(APIs), excipients, packing materials, and/or synthesis
processes of APIs, are the prime factors delineated for
NA formation [9]. For example, one of the root causes
of the formation of NA impurities indicated in the
FDA reports is that the APIs containing secondary or
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tertiary amine functional groups are susceptible to
degradation under certain reaction conditions
because the trace impurities from degraded APIs may
react with nitrous acid or other nitrosating agents to
form NAs under acidic conditions [8]. Thus, the
presence of substructures of secondary or tertiary
amine groups in APIs, excipients, or other materials
might serve as an indicator to predict the potential
risks of residual NA impurities in pharmaceuticals.
The regulatory agencies acted quickly to recall
medications and pre-emptively test them to remove
contaminated products from the market, continued to
investigate other drug products, and advised pharmaceutical companies to take appropriate actions.
However, the issue of a sudden lack of medicine still
urges both regulatory agencies and pharmaceutical
industries to develop a rapid screening approach to
comprehensively evaluate marketed products. Hitherto, limited strategies have been available to efﬁciently identify medications that tend to produce NAs
from various drug substances. Text mining, the most
widely used approach for collecting historical results
and conducting retrospective analysis, is an expertoriented but labor-intensive methodology. Thus, a
structure-based (i.e., substructure moiety) searching
method capable of deriving the possible presence of
NA impurities in drug products with superior efﬁciency would be highly regarded.
In this study, a structure-based method was established to determine the risks of NA impurities via
mining eight types of substructures (i.e., seven identiﬁed amine sources of NAs and a tetrazole ring) in
pharmaceuticals. Using DataWarrior, an open-source
chemoinformatic software [10], the candidate compounds among all commercial drug substances were
quickly identiﬁed, while their structural mark matched
the deﬁned NA substructures. In theory, NAs produced in drug products are related to the nitrogencontaining functional groups of reagents, solvents,
catalysts, and/or APIs. The remnant of a NA-related
structural mark in API can be ﬁrst-hand evidence to
differentiate whether these susceptible chemicals (i.e.,
as reagents) have been used in the synthesis of API.
Since any newly identiﬁed NA root substructure can
be added into the screening template, this computeraided technique provides an effective and expandable
methodology for risk assessments of potential NA
impurities in pharmaceuticals [11].

2. Methods
2.1. Dataset preparation
To employ the screening feature of the method, a
data ﬁle of approved small-molecule drugs with
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canonical simpliﬁed molecular-input line-entry system (SMILES) codes was prepared from DrugBank
Release Version 5.1.7 (https://go.drugbank.com) for
text encoding their chemical structures. This version
contains 10,767 drug entries, including 2,471
approved small-molecule drugs (the collection of the
FDA, Canada, and EMA approvals, but also including
some withdrawn drug products), 107 nutraceuticals,
and over 6,041 experimental (discovery-phase) drugs.
However, only the data subset of approved smallmolecule drugs was used in the study [12].

2.3. Virtual screening based on NA-related
substructures

2.2. NA-related substructures’ deﬁnitions

2.4. Method validation

As mentioned previously, the FDA has identiﬁed
seven NA impurities that can exist in drug products.
Besides NDMA, NAs include N-nitrosodiethylamine
(NDEA), N-nitroso-N-methyl-4-aminobutanoic acid
(NMBA), N-nitrosoisopropylethylamine (NIPEA), Nnitrosodiisopropylamine (NDIPA), N-nitrosodibutylamine (NDBA), and N-nitrosomethylphenylamine
(NMPA) [9]. Theoretically, these NAs are formed
from precursors such as dimethylamine (DMA),

Since the outcome of the virtual screening deﬁned
above indicated the possibility of NA impurities
produced in pharmaceuticals, we used the index of
sensitivity to validate this qualitative method. The
APIs reported in the literature [14] with proven NA
contamination were used to check the sensitivity
index and were deﬁned as the proportion of real
positive cases that had been correctly identiﬁed [15].
For calculation, sensitivity was expressed as follows:

Sensitivity ¼

The data of 2,471 small-molecule compounds
were imported into Osiris DataWarrior 5.2.1 [10]
and subjected to substructure screening. The virtual
screening of the compounds suspected of having
NA impurities was performed with the function
“Add Substructure Count.” The search algorithm
was then automatically run for each “query”
substructure.

Number of the literature  reported cases detected using this method
Number of positive cases reported in reference literature

diethylamine (DEA), isopropylethylamine (IPEA),
diisopropylamine (DIPA), N-methyl-4-aminobutanoic
acid (MBA), dibutylamine (DBA), and methylphenylamine (MPA) to react with nitrate under acidic conditions. Except for MBA, the six precursors were deﬁned
as NA-related substructures used in the query process.
According to the European Medicines Agency (EMA)
report in 2019, N-methyl-2-pyrrolidone (NMP) is converted to MBA through hydrolytic degradation; MBA
can further undergo nitrosation into NMBA, a known
animal and potential human carcinogen [13]. Therefore, we deﬁned NMP as the NA-related substructure
for MBA formation. Furthermore, previous reports
have indicated that NDMA may be formed during the
synthesis of tetrazole rings with the use of azides and
dimethylformamide (DMF) as solvent [14], and several
tetrazole drugs such as cephalosporins and cilostazol
have been reported to be contaminated with NDMA.
Consequently, tetrazole was set as the NA-related
substructure for screening the possibility of NDMA
impurities. Altogether, eight NA-related substructures, shown in Fig. 1, were selected for in-depth
investigation in this study.

2.5. Scalability
One latest warning letter regarding NA impurities
in market drugs was issued by FDA in August 2020,
concerning about the presence of 1-methyl-4-nitrosopiperazine (MNP) in rifampin and 1-cyclopentyl4-nitrosopiperazine (CPNP) in rifapentine [16].
Therefore, the root NA-precursors of these impurities - 1-methyl-piperazine (MP) and 1-cyclopentylpiperazine (CPP) moieties were set as the additional
substructures for testing the scalability of this
screening method.

3. Results
The results from the DataWarrior showed that 195
drugs met the screening criteria. Among these drugs,
dimazole, cefotiam, and pramiracetam were found to
contain two types of NA-related substructures,
resulting in double counting (Fig. 2). Thus, a total
of 192 drugs with the theoretical possibility of NA
impurity production were detected using this
method.
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Fig. 1. Eight substructures present in the drug substances of interest. DBA, dibutylamine; DEA, diethylamine; DIPA, diisopropylamine; DMA,
dimethylamine; IPEA, isopropylethylamine; MPA, methylphenylamine; NMP, N-methyl-2-pyrrolidone.

In the subgroup analysis, 124 compounds were
found with a DMA moiety, 38 compounds with a
DEA moiety, and 22 compounds with a tetrazole
(Table 1).
The structural formulae of all approved drugs
meeting the screening criteria mentioned above are
shown in the Supplemental data.
During validation based on literature data [14], 4
out of 58 APIs with known or suspected precursors
of NAs, including methapyrilene, methyl orange,
methylene blue, and oleandomycin, were not
detected because they were not collected in
Table 1. Numbers of screening results for eight substructures.
Substructures

Numbers
(Double counting)

Double counting
drugs

DMA
DEA
DIPA
IPEA
NMPa
MPA
DBA
Tetrazole

122 (2)
38
3 (1)
0
3
0
4
22

Dimazole, Cefotiam
Dimazole
Pramiracetam

Total

192

a

Pramiracetam

Cefotiam

NMP is a root cause of MBA according to the EMA report
2019.

Drugbank as approved drugs (Table 2). Among the
54 real positive APIs, only three, namely aminopyramine, benzalkonium chloride, and chloramphenicol, were not detected with this method,
yielding a detection sensitivity of 0.944. This high
sensitivity suggests that our approach could efﬁciently detect suspicious APIs from Drugbank's API
pool with high accuracy.
In the scalability testing of this method, 33 out of
2,471 approved drugs were quickly identiﬁed as the
suspected NA-contaminated compounds by using
MP and CPP moieties as the ﬁltering substructures.
A detailed list of APIs containing the MP and CPP
moieties can be found in Table 3.

4. Discussion
The present study is the ﬁrst to demonstrate an
effective and scalable screening methodology for the
identiﬁcation of possible NA impurities in drug
substances by matching the substructure of APIs
with NA precursors using open-source software.
This method effectively indicates suspicious drug
substances from a comprehensive API library pool
using the artiﬁcial intelligence technique of
cheminformatics.

Fig. 2. Double counting compounds: dimazole, cefotiam, and pramiracetam.
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Table 2. Active pharmaceutical ingredients reported as known or suspected precursors of N-nitrosamines.
Order

Compounds

Order

Compounds

Order

Compounds

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Aminopyraminea
Alfentanil
Aminophenazone
Amitriptyline
Azithromycin
Benzalkonium Chloridea
Candesartan
Carbinoxamine
Cefamandole
Cefazolin
Cefmenoxime
Cefonicid
Cefoperazone
Cefotetan
Cefotiam
Cefpiramide
Chloramphenicola
Chlorpheniramine
Chlorpromazine
Chlorprothixene

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Chlortetracycline
Cilostazol
Citalopram
Clarithromycin
Clomipramine
Diethyltoluamide
Diltiazem
Dimenhydrinate
Diphenhydramine
Doxepin
Doxylamine
Erythromycin
Escitalopram
Imipramine
Irbesartan
Losartan
Meropenem
Metformin
Methapyrileneb
Methyl Orangec

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

Methylene Blueb
Mifepristone
Minocycline
Nizatidine
Oleandomycind
Olmesartan
Oxytetracycline
Promazine
Propoxyphene
Quinupristin
Ranitidine
Roxithromycin
Spiramycin
Sumatriptan
Tetracycline
Tramadol
Trimipramine
Venlafaxine

Drugbank dataset covers drug products approved by the FDA, Health Canada and EMA; including some withdrawn drug products as
well.
a
Aminopyramine, benzalkonium chloride, and chloramphenicol were not detected.
b
Methapyrilene was withdrawn from the market in 1979.
c
Methyl orange and methylene blue are not collected in Drugbank as approved drugs.
d
Oleandomycin, a synthesized macrolide antibiotic, is an approved vet medicine.

When confronting the risk assessments and surveillances for the massive amount of marketed
pharmaceutical products, implementing such a
cheminformatics tool to detect the possibility of NA
impurities in pharmaceutical substances would be
much more efﬁcient and comprehensive than
analyzing those substances item by item in the
laboratory. DataWarrior is an open-source chemical
software that facilitates the visual and quantitative
analysis of information relevant to drug discovery.
The user can input a chemical structure using the
text coding of the SMILES string, and DataWarrior
can automatically convert this code into a chemical
structure with the corresponding atom coordinates.
The built-in chemistry intelligence allows working
with chemical structures as easily as with alphanumeric data. In this study, the ﬁlter function we
utilized was a substructure ﬁlter, which possesses
the features of a ﬂexible query and real-time

ﬁltering. By running this function, the search for a
given substructure in a molecule's structure is
readily achieved. In addition, this function allows
the manual deﬁnition of the atom and/or bond
features of the query fragment to narrow down the
search results.
Compared to the conventional methodologies,
the developed cheminformatics-based methodology has tremendous advantages to carry out NA
risk assessments, with profound effectiveness and
scalability [11]. This study utilized the structuremining methodology, which enabled comprehensive screening of all commercial APIs by merely
setting suspicious NA-related substructures. In
contrast, conventional methods based on text-mining methodology have a low throughput because
these kinds of analyses are all based on retrospective literature analysis, which is very time
consuming. Nevertheless, this study provides an

Table 3. Active pharmaceutical ingredients identiﬁed containing the R-piperazine moieties (MP&CPP).
Substructure moiety

Root case

Other compounds

Rifampicin

Bosutinib, Brigatinib, Butaperazine, Chlorcyclizine, Clothiapine,
Clozapine, Cyclizine, Diethylcarbamazine, Entrectinib, Eszopiclone,
Fosnetupitant, Gilteritinib, Hexocyclium, Imatinib, Levoﬂoxacin,
Loxapine, Netupitant, Nintedanib, Oﬂoxacin, Olanzapine,
Peﬂoxacin, Perazine, Pipecuronium, Pirenzepine, Ponatinib,
Prochlorperazine, Sildenaﬁl, Thiethylperazine, Thiothixene,
Triﬂuoperazine, Zopiclone

Rifapentine

None

effective and prospective way to perform NA risk
assessment for both pharmaceutical regulatory
agencies and industries.
Another advantage of our approach is that it can
be scaled for other NA impurities such as 1-methyl4-nitrosopiperazine (MNP) and 1-cyclopentyl-4nitrosopiperazine (CPNP), as long as the theoretical
basis for the formation of these NA impurities can
be established. Among 33 drugs with the theoretical
possibility of NA impurity production, only rifapentine contained a CPP moiety, and the remaining
suspected compounds all contained the MP moiety,
implying that the cases of MNP contamination in
pharmaceuticals might be more severe.
During validation of our screening results by
analyzing known cases in the literature [14], we found
that our method failed to detect quinupristin, irbesartan, and losartan. Modifying the query of the DMA
substructure, the appended sub-query for the moiety
fragment coordinated to double-bond structures
including azo linkages, imine linkages, and aromatic
rings, resulting in 10 new hits in the API screening,
including dacarbazine (azo), altretamine (imine),
iopodic acid (imine), gentian violet cation (aromatic),
methylene blue (aromatic), quinupristin (aromatic),
pyrvinium (aromatic), ulipristal (aromatic), pamidate
O (aromatic), and mifepristone (aromatic). Among
these substances, methylene blue was previously reported as a precursor of NA impurity.
While quinupristin could be detected through our
approach with the appendix of sub-query, the
antihypertensive drugs irbesartan and losartan
exhibiting known issues of NA impurities omitted in
the ﬁrst screening run, still needed further investigation. In this regard, we found that the tetrazole
ring can exist in two tautomeric forms [17,18], which
mutually convert between 1H-tetrazole and 2H-tetrazole. Considering our previous query setting
including only 1H-tetrazole, some tetrazole compounds might be omitted. The screening query was
revised with the addition of tautomeric 2H-tetrazole,
and the results covered all the aforementioned sartans, including irbesartan, losartan, valsartan, and
pemirolast, as well as tedizolid and tedizolid phosphate. These results showed that our approach
could provide a very accurate screening via welland precisely deﬁned query settings.
As indicated in the Results section, aminopyramine, benzalkonium chloride, and chloramphenicol were not detected using our approach, although
they are documented in the literature to contain
NAs. Therefore, we analyzed the possible causes of
this omittance and found that aminopyramine and
chloramphenicol do not have a structural fragment
matching the eight NA-related substructures used

in this study. According to studies on the variation
of NDMA content in aminopyramine-containing
products, it was found that tablet and suppository
formulations have higher levels of NDMA, suggesting that the production of NDMA impurities
may be associated with other pharmaceutical components, such as excipients and packaging materials, which have been used in the entire lifecycle of
drug products, and their amounts vary among
different formulations [19]. On the contrary, in
addition to our approach, it appeared that universal
NA analysis was still needed as a second-line
method to reduce the risk of NA impurities for some
nitrogen-containing compounds. In accordance,
chloramphenicol was not detected through our
approach. Thus, the proposal of new NA-related
substructures based on the organic chemistry theorem will help greatly improve the comprehensiveness and effectiveness of our approach [20].
Furthermore, it was found that benzalkonium
chloride, a class of quaternary ammonium antimicrobial agents, could not be detected with our
approach; however, this result was misleading.
Quaternary ammonium salts may contain residual
secondary and tertiary amines as impurities or
degradants, and the presence of quaternary amines
and trace nitrite salts under acidic reaction conditions are known to generate NA impurities. After
carefully examining our dataset, it was found that
benzalkonium chloride could not be classiﬁed as an
approved drug in Drugbank; therefore, it was not
detected using our approach. To solve this issue,
other chemical databases such as ChEMBL can be
integrated to expand the compound coverage of the
dataset and enrich the sensitivity of our approach.
Notably, among eight structural fragments used in
this study to detect NA impurities, DMA, DEA
moieties, and tetrazole ring were found to be the
primary substructures with the highest hit rates in
Table 4. The numbers of new active pharmaceutical ingredients in each
sub-group.
Substructures

Hit
numbers

Conﬁrmed
numbers [14]

Undiscovered
numbers

DMA
DEA
DIPA
IPEA
NMP
MPA
DBA
Tetrazole

122
38
3
0
3
0
4
22

37
1
0
0
0
0
0
13

85
37
3
0
3
0
4
9

Total

192

51

141

DBA, dibutylamine; DEA, diethylamine; DIPA, diisopropylamine;
DMA, dimethylamine; IPEA, isopropylethylamine; MPA, methylphenylamine; NMP, N-methyl-2-pyrrolidone.
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detecting suspicious APIs. Using the known cases
cited in the literature [14] for subtraction, this study
showed that our approach disclosed 141 drug substances with possible NA impurities (Table 4).
In this study, DMA was found to be the most sensitive substructure for detecting suspicious drug
substances. This moiety detected 122 suspicious drug
substances, with 37 proven cases having the risk of NA
impurities. Several of the remaining 85 compounds
were also evident in the literature. For example, triptans are used for the treatment of severe migraine
attacks or patients who do not respond to NSAIDs or
other over-the-counter drugs. Several triptans,
including sumatriptan, zolmitriptan, almotriptan, and
rizatriptan, with DMA moieties were detected with
our approach. Structurally, sumatriptan's DMA fragment is bound to an electron-donating indole ring, as
demonstrated in a recent study [21], and could form
NDMA in NA-formation potential tests with a molar
conversion rate of more than 6% [22]. Therefore, both
pharmaceutical manufacturers and regulatory authorities were aware of the risk of NDMA formation in
sumatriptan. Nevertheless, according to our
screening results, a warning for NDMA risk in other
triptans such as zolmitriptan, almotriptan, and rizatriptan should be also be given [14].
On the other hand, it is known that amine-based
pharmaceuticals and personal care products (PPCPs)
containing DMA or DEA in their structures that
could contribute to NA formation during chloramine
disinfection of water [21]. While our method could
detect all twenty PPCPs including two DEA compounds (i.e., diethyltoluamide (DEET) and lidocaine)
tested in the study, it is worthy to note that these
DEA-related compounds with the susceptible NA
problem can be liberally underestimated.
In this study, the screening library was limited to a
pool of APIs. Therefore, our approach ran with no
hits for two substructure groups: isopropylethylamine (IPEA) and methylphenylamine (MPA) [16].
After further examination, the root causes of no hits
were rationalized as follows: 1) either IPEA or MPA is
the side product of the nitrogen-containing reagent;
2) IPEA or MPA is present in small amounts in the
reagent or solvent; 3) IPEA or MPA is not involved in
the synthesis of API and therefore does not integrate
into API's structure as a structural mark. In fact, the
route of IPEA formation was identiﬁed owing to the
use of tertiary diisopropylethylamine (DIPEA) as a
reagent in API synthesis. DIPEA consists of a tertiary
hindered nitrogen that is bonded to an ethyl group
and two isopropyl groups, commonly employed as a
proton scavenger in several reactions, such as alkylation and amide coupling [23]. The DIPEA reagent
might undergo de-alkylation to give the tertiary

amine IPEA, following the occurrence of N-nitrosation with nitrite sources, yielding ethylisopropylN-NA (EIPNA). Similarly, N-dimethylaniline is expected to be a potential source of N-methylaniline
(another name of MPA).
The NMP moiety was detected in three suspicious
drug substances: piracetam, levetiracetam, and pramiracetam. However, one study showed that the
NMP moiety was degraded under alkaline stress
conditions, instead of acidic conditions [24,25], which
are essential for NA impurity formation. Although
we would infer that those piracetam-like drugs bear a
lower risk of NA formation compared to DMA moiety-containing drugs, appropriate measures are
recommended as these solvents/reagents are
commonly used and unavoidable.
In summary, the effectiveness or impotence of our
approach utilizing a substructure-matching technique to detect the risks of NA impurities mainly
depends on the compound library used. The potential presence of tertiary amine impurities in solvents,
reagents, and/or catalysts requires the addition of a
solvent/reagent/catalyst library for the detection of
side products. While awareness and detection of NAs
have increased in recent years, our approach could
provide a rapid and effective method to estimate the
risk of NA impurities in pharmaceuticals.

5. Conclusion
Our study shows that numerous of drug substances are still undiscovered yet bear a potential to
produce NAs, DMA-containing drug substances
taking the lead. The screening process used could
provide a practical risk assessment strategy
involving an effective and scalable method for
screening and investigation of NA impurities in
various pharmaceuticals. Additionally, the validation data reﬂected the method's compliance in line
with the regulatory expectations and requirements
and published literature. Our approach has successfully demonstrated broad applicability not only
for drug substances but also possibly for nutraceuticals and investigational products.
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Appendix. Supplemental data

Fig. S1. The screening results for DMA candidates.
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Fig. S1. (continued)
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Fig. S1. (continued)

Fig. S2. The screening results for DEA candidates.
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Fig. S3. The screening results for DIPA candidates.

Fig. S4. The screening results for NMP candidates.

Fig. S5. The screening results for DBA candidates.

Fig. S6. The screening results for tetrazoles candidates.
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Fig. S7. The screening results for MP candidates.
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